102129-66-8

102129-66-8 structure

Name: ALA-ALA-PHE-CHLOROMETHYLKETONE TFA
Chemical Name: (2S)-2-amino-N-[(2S)-2-[[(2S)-4-chloro-3-oxo-1-phenylbutan-2-yl]amino]propanoyl]propanamide
CAS Number: 102129-66-8
Molecular Formula: C₁₆H₂₂ClN₃O₃
Molecular Weight: 339.81700
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2017-01-02 19:54:24
Modify Date: 2026-07-04 12:50:37
AAF-CMK is a TPPII (tripeptidylpeptidase II) inhibitor, shows anti-tumor activity and induces apoptosis. AAF-CMK can be used in leukemia research[1].

Name	(2S)-2-amino-N-[(2S)-2-[[(2S)-4-chloro-3-oxo-1-phenylbutan-2-yl]amino]propanoyl]propanamide
Synonyms	ALA-ALA-PHE-CMK TFA H-ALA-ALA-PHE-CMK TFA (L-ALANYL-L-ALANYL-L-PHENYLALANYL)CHLOROMETHANE TRIFLUOROACETATE AAF-CMK TRIFLUOROACETATE AAPCK L-Alaninamide,l-alanyl-N-[(1S)-3-chloro-2-oxo-1-(phenylmethyl)propyl] H-ALA-ALA-PHE-CHLOROMETHYLKETONE TFA TRIPTIDYLPTIDASE II INHIBITOR AAF-CMK TFA H-AAF-CMK, TFA ALA-ALA-PHE-CH2CL TRIFLUOROACETATE Ala-Ala-Phe-CH2Cl [AAF-CMK] (5 mg vial) alanyl-alanyl-phenylalanine chloromethyl ketone Alanyl-alanyl-phenylalanine chloromethyl ketone H-Ala-Ala-Phe-CMK Ala-ala-phe-chloromethyl ketone

Description	AAF-CMK is a TPPII (tripeptidylpeptidase II) inhibitor, shows anti-tumor activity and induces apoptosis. AAF-CMK can be used in leukemia research[1].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Ser/Thr Protease Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer
In Vitro	AAF-CMK (0-20 μM; 24 h) shows potentiated antitumor effects of U937 leukemia cells in combination with TRAIL or TNF[1]. AAF-CMK (20 μM; 24 h) increases TNF- and TRAIL-induced U937 cell apoptosis[1]. Cell Viability Assay[1] Cell Line: U937 human promonocytic leukemia cells Concentration: 0-20 μM Incubation Time: 24 h Result: Resulted in the potentiation of growth inhibitory cytostatic effects of TRAIL as well as TNF. Apoptosis Analysis[1] Cell Line: U937 human promonocytic leukemia cells Concentration: 20 μM Incubation Time: 24 h Result: Increased the percentage of apoptotic cells to 55.8% in combination with TRAIL. Increased number of cells with characteristic apoptotic morphology in groups treated with AAF-CMK and both TRAIL or TNF compared to each group treated alone.